Optic neuritis: current challenges in diagnosis and management

Purpose of review The primary aim of this review is to describe the clinical course, salient imaging features, and relevant serological profiles of common optic neuritis (ON) subtypes. Key diagnostic challenges and treatment options will also be discussed. Recent findings ON is a broad term that describes an inflammatory optic nerve injury arising from a variety of potential causes. ON can occur sporadically, however there is particular concern for co-associated central nervous system (CNS) inflammatory syndromes including multiple sclerosis (MS), neuromyelitis optic spectrum disorders (NMOSD), and myelin oligodendrocyte glycoprotein antibody associated disease (MOGAD). The ON subtypes that often herald MS, NMOSD, and MOGAD differ with respect to serological antibody profile and neuroimaging characteristics, yet there is significant overlap in their clinical presentations. A discerning history and thorough examination are critical to rendering the correct diagnosis. Summary Optic neuritis subtypes vary with respect to their long-term prognosis and accordingly, require different acute treatment strategies. Moreover, delays in identifying MOGAD, and certainly NMOSD, can be highly detrimental because affected individuals are vulnerable to permanent vision loss and neurologic disability from relapses.

[1]  N. Newman,et al.  Optic neuritis and autoimmune optic neuropathies: advances in diagnosis and treatment , 2022, The Lancet Neurology.

[2]  F. Costello,et al.  A Practical Approach to the Diagnosis and Management of Optic Neuritis , 2022, Annals of Indian Academy of Neurology.

[3]  T. Chitnis,et al.  Positive Predictive Value of MOG-IgG for Clinically Defined MOG-AD Within a Real-World Cohort , 2022, Frontiers in Neurology.

[4]  Jacqueline Palace,et al.  Association of Maintenance Intravenous Immunoglobulin With Prevention of Relapse in Adult Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. , 2022, JAMA neurology.

[5]  S. Saidha,et al.  OCT retinal nerve fiber layer thickness differentiates acute optic neuritis from MOG antibody-associated disease and Multiple Sclerosis: RNFL thickening in acute optic neuritis from MOGAD vs MS. , 2022, Multiple sclerosis and related disorders.

[6]  À. Rovira,et al.  Drug-related demyelinating syndromes: understanding risk factors, pathophysiological mechanisms and magnetic resonance imaging findings. , 2021, Multiple sclerosis and related disorders.

[7]  Ethan Meltzer,et al.  Neuromyelitis Optica Spectrum Disorders (NMOSD) and Connective Tissue Disease (CTD): an Update for the Rheumatologist , 2021, Current Rheumatology Reports.

[8]  B. Weinshenker,et al.  Positive Predictive Value of Myelin Oligodendrocyte Glycoprotein Autoantibody Testing , 2021, JAMA neurology.

[9]  J. Bennett,et al.  The changing landscape of optic neuritis: a narrative review , 2021, Journal of Neurology.

[10]  Jacqueline Palace,et al.  New therapies for neuromyelitis optica spectrum disorder , 2020, The Lancet Neurology.

[11]  F. Paul,et al.  Neuromyelitis optica , 2020, Nature Reviews Disease Primers.

[12]  A. Kermode,et al.  Risk of relapse in patients with neuromyelitis optica spectrum disorder: Recognition and preventive strategy. , 2020, Multiple sclerosis and related disorders.

[13]  F. Paul,et al.  Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: Results from 163 lumbar punctures in 100 adult patients , 2020, Journal of Neuroinflammation.

[14]  D. Hodge,et al.  Population based incidence of optic neuritis in the era of aquaporin-4 and myelin oligodendrocyte glycoprotein antibodies. , 2020, American journal of ophthalmology.

[15]  O. Ciccarelli,et al.  Treatment of MOG antibody associated disorders: results of an international survey , 2020, Journal of Neurology.

[16]  B. Weinshenker,et al.  Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder , 2020, Neurology.

[17]  Jacqueline Palace,et al.  Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients. , 2020, Multiple sclerosis and related disorders.

[18]  Paul P. Lee,et al.  Association of Individual-Level Factors With Visual Outcomes in Optic Neuritis , 2020, JAMA Network Open.

[19]  A. Traboulsee,et al.  Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial , 2020, The Lancet Neurology.

[20]  Chunshui Yu,et al.  Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial , 2020, The Lancet Neurology.

[21]  T. Misu,et al.  Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial , 2020, The Lancet Neurology.

[22]  N. Newman The Optic Neuritis Treatment Trial. , 2020, Ophthalmology.

[23]  Jacqueline Palace,et al.  Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder. , 2019, The New England journal of medicine.

[24]  John J. Chen,et al.  Clinical Characteristics and Treatment of MOG-IgG–Associated Optic Neuritis , 2019, Current Neurology and Neuroscience Reports.

[25]  Gary R Cutter,et al.  Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial , 2019, The Lancet.

[26]  Ashwini Hiremath,et al.  Plasma Exchange as a First Line Therapy in Acute Attacks of Neuromyelitis Optica Spectrum Disorders , 2019, Annals of Indian Academy of Neurology.

[27]  Tiansong Zhang,et al.  Effectiveness and tolerability of immunosuppressants and monoclonal antibodies in preventive treatment of neuromyelitis optica spectrum disorders: A systematic review and network meta-analysis. , 2019, Multiple sclerosis and related disorders.

[28]  O. Mimura,et al.  Epidemiologic and Clinical Characteristics of Optic Neuritis in Japan. , 2019, Ophthalmology.

[29]  J. Kira,et al.  Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD , 2019, Neurology.

[30]  M. Bach,et al.  Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis? , 2019, Neurology: Neuroimmunology & Neuroinflammation.

[31]  Jacqueline Palace,et al.  Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. , 2019, The New England journal of medicine.

[32]  D. Wingerchuk Disease-modifying therapies should be stopped in NMOSD patients in remission – Commentary , 2019, Multiple sclerosis.

[33]  J. Mills,et al.  A multicenter comparison of MOG-IgG cell-based assays , 2019, Neurology.

[34]  J. P. Ospina,et al.  Outcomes from acute attacks of neuromyelitis optica spectrum disorder correlate with severity of attack, age and delay to treatment. , 2019, Multiple sclerosis and related disorders.

[35]  D. Sato,et al.  Persistent MOG-IgG positivity is a predictor of recurrence in MOG-IgG-associated optic neuritis, encephalitis and myelitis , 2018, Multiple sclerosis.

[36]  B. Weinshenker,et al.  Myelin Oligodendrocyte Glycoprotein Antibody-Positive Optic Neuritis: Clinical Characteristics, Radiologic Clues, and Outcome. , 2018, American journal of ophthalmology.

[37]  Fiona Costello,et al.  The role of optical coherence tomography in neuro-ophthalmology , 2018 .

[38]  J. A. Fraser,et al.  Effect of Treating Acute Optic Neuritis With Bioequivalent Oral vs Intravenous Corticosteroids: A Randomized Clinical Trial , 2018, JAMA neurology.

[39]  F. Costello,et al.  Transient vision loss: a neuro-ophthalmic approach to localizing the diagnosis , 2018 .

[40]  David H. Miller,et al.  Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria , 2017, The Lancet Neurology.

[41]  N. Kung,et al.  Incidence and Causes of Overdiagnosis of Optic Neuritis , 2018, JAMA ophthalmology.

[42]  P. Cabre,et al.  Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders , 2017, Journal of Neurology, Neurosurgery, and Psychiatry.

[43]  V. Shaygannejad,et al.  Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial , 2017, Journal of Neurology.

[44]  K. Fujihara,et al.  Neuromyelitis Optica Spectrum Disorders. , 2017, Neuroimaging clinics of North America.

[45]  D. Wingerchuk,et al.  Transient smartphone blindness: Relevance to misdiagnosis in neurologic practice , 2017, Neurology.

[46]  Lynn D. Hudson,et al.  Validity of low-contrast letter acuity as a visual performance outcome measure for multiple sclerosis , 2017, Multiple sclerosis.

[47]  V. Lennon,et al.  Clinical utility of testing AQP4-IgG in CSF , 2016, Neurology: Neuroimmunology & Neuroinflammation.

[48]  J. Joo,et al.  Comparative analysis of treatment outcomes in patients with neuromyelitis optica spectrum disorder using multifaceted endpoints , 2016, Multiple sclerosis.

[49]  D. Reich,et al.  Revised Recommendations of the Consortium of MS Centers Task Force for a Standardized MRI Protocol and Clinical Guidelines for the Diagnosis and Follow-Up of Multiple Sclerosis , 2016, American Journal of Neuroradiology.

[50]  F. Paul,et al.  Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses , 2016, Annals of neurology.

[51]  J. Joo,et al.  Treatment Outcomes With Rituximab in 100 Patients With Neuromyelitis Optica: Influence of FCGR3A Polymorphisms on the Therapeutic Response to Rituximab. , 2015, JAMA neurology.

[52]  A. Traboulsee,et al.  International consensus diagnostic criteria for neuromyelitis optica spectrum disorders , 2015, Neurology.

[53]  Jacqueline Palace,et al.  Neuromyelitis optica and multiple sclerosis: Seeing differences through optical coherence tomography , 2015, Multiple sclerosis.

[54]  S. Galetta,et al.  Analysis of the treatment of neuromyelitis optica , 2015, Journal of the Neurological Sciences.

[55]  Jacqueline A Palace,et al.  Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. , 2014, JAMA neurology.

[56]  J. Horton,et al.  Microcysts in the inner nuclear layer from optic atrophy are caused by retrograde trans-synaptic degeneration combined with vitreous traction on the retinal surface. , 2013, Brain : a journal of neurology.

[57]  G. Plant,et al.  Distinguishing Optic Neuritis in Neuromyelitis Optica Spectrum Disease From Multiple Sclerosis: A Novel Magnetic Resonance Imaging Scoring System , 2013, Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society.

[58]  A. McKinney,et al.  Accuracy of routine fat-suppressed FLAIR and diffusion-weighted images in detecting clinically evident acute optic neuritis , 2013 .

[59]  N. Volpe The optic neuritis treatment trial: a definitive answer and profound impact with unexpected results. , 2008, Archives of ophthalmology.

[60]  Melvin Greer,et al.  Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. , 2008, Archives of neurology.

[61]  Y. Itoyama,et al.  Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis , 2007, Multiple sclerosis.

[62]  Ichiro Nakashima,et al.  A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis , 2004, The Lancet.

[63]  J. Corbett Experience of the optic neuritis treatment trial , 2004, Current Neurology and Neuroscience Reports.

[64]  M. Kupersmith,et al.  Contrast-enhanced MRI in acute optic neuritis: relationship to visual performance. , 2002, Brain : a journal of neurology.

[65]  A. Vighetto,et al.  [Inflammatory optic neuropathies]. , 2001, La Revue du praticien.

[66]  Chris A. Johnson,et al.  Comparison of central and peripheral visual field properties in the optic neuritis treatment trial. , 1996, American journal of ophthalmology.

[67]  R. Beck,et al.  The course of visual recovery after optic neuritis. Experience of the Optic Neuritis Treatment Trial. , 1994, Ophthalmology.

[68]  Neil R. Miller,et al.  A Randomized, Controlled Trial of Corticosteroids in the Treatment of Acute Optic Neuritis , 1992 .

[69]  The clinical profile of optic neuritis. Experience of the Optic Neuritis Treatment Trial. Optic Neuritis Study Group. , 1991, Archives of ophthalmology.

[70]  V. Lennon,et al.  Clinical utility of testing AQP4-IgG in CSF , 2016, Neurology: Neuroimmunology & Neuroinflammation.